Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Prognostic value of primary tumor SUVmax on pre-treatment 18F-FDG PET/CT imaging...
Journal Information
Vol. 37. Issue 4.
Pages 218-222 (July - August 2018)
Share
Share
Download PDF
More article options
ePub
Visits
9
Vol. 37. Issue 4.
Pages 218-222 (July - August 2018)
Original Article
DOI: 10.1016/j.remnie.2017.12.001
Prognostic value of primary tumor SUVmax on pre-treatment 18F-FDG PET/CT imaging in patients with stage III non-small cell lung cancer
Valor pronóstico del SUVmax del tumor primario pre-tratamiento con PET/TC con 18F-FDG en pacientes con cáncer de pulmón no microcítico en estadio III
Visits
...
Ufuk Yılmaza,
Corresponding author
ufukyilmazdr@gmail.com

Corresponding author.
, Özgür Batuma, Hakan Koparalb, Engin Özbilekb, Esra Kıraklıc
a Department of Pulmonology, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey
b Department of Nuclear Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey
c Department of Radiation Oncology, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Characteristics of patient subgroups.
Table 2. Univariate and multivariate analysis of variables for overall survival.
Table 3. Univariate and multivariate analysis of variables for progression free survival.
Show moreShow less
Abstract
Objectives

Concomitant chemoradiotherapy (CCRT) is widely used in the treatment of patients with stage III non-small lung carcinoma (NSCLC). The early identification of patients with poor prognosis is the premise of personalized treatment for patients. The aim of the study was to evaluate the prognostic value of clinical parameters and primary tumor SUVmax on pre-treatment 18F-FDG PET/CT in patients with stage III NSCLC.

Material and methods

Clinical records of 79 stage III-NSCLC patients with pre-treatment 18F-FDG PET/CT imaging, treated with definitive CCRT were retrospectively reviewed. The clinical endpoints in terms of progression-free survival (PFS) and overall survival (OS) were correlated with the median pre-treatment primary tumor SUVmax. Furthermore, other factors influencing patient outcome were analyzed.

Results

The median age of patients was 58 years (range, 45–71) with 72 (91%) males. Squamous cell carcinoma (73%) was the most common histologic type. Performance status was very good (ECOG 0) in 64.5% of patients. Sixty (79%) patients had died at the time of this analysis. Median OS and PFS were 22.5 and 12.0 months, respectively. Patients were dichotomized according to pre-treatment primary tumor SUVmax ≤15.0 vs >15.0. There was no statistically significant difference for OS and PFS in both arms. Multivariate analysis showed that pre-treatment SUVmax was not a significant predictor of OS (HR 1.099, p=0.726) and PFS (HR 1.022, p=0.941).

Conclusions

SUVmax with threshold value of 15.0 on the primary tumor before treatment had no prognostic value in our patient group with stage III NSCLC treated with definitive CCRT.

Keywords:
Prognosis
18F-FDG PET/CT
Chemoradiotherapy
Lung cancer
Resumen
Objetivos

La quimioradioterapia concomitante (CCRT) se utiliza de forma amplia para tratar a los pacientes con cáncer de pulmón no microcítico (CPCP) en estadio III. La identificación precoz de los pacientes con mal pronóstico constituye la premisa del tratamiento personalizado de los pacientes. El objetivo de este estudio fue evaluar el valor pronóstico de los parámetros clínicos y SUVmax del tumor primario sobre PET/TC con 18F-FDG pre-tratamiento en los pacientes con CPCP en estadio III.

Material y métodos

Se revisaron retrospectivamente las historias clínicas de 79 pacientes de CPCP en estadio III con PET/TC con 18F-FDG pre-tratamiento, tratados con CCRT definitiva. Se correlacionaron los criterios de evaluación clínicos en términos de supervivencia libre de progresión (SLP) y supervivencia global (OS) con el valor SUVmax medio del tumor primario pre-tratamiento. Además, también se analizaron otros factores de influencia en el resultado del paciente.

Resultados

La edad media de los pacientes fue de 58 años (rango, 45-71), con 72 (91%) varones. El carcinoma de células escamosas (73%) fue el tipo histológico más común. El estatus del desempeño fue muy bueno (ECOG 0) en el 64,5% de los pacientes. Sesenta (79%) pacientes habían fallecido en el momento de este análisis. Los valores medios de OS y SLP fueron de 22,5 y 12 meses, respectivamente. Los pacientes se dicotomizaron con arreglo a SUVmax del tumor primario pre-tratamiento ≤15 vs >15. No se encontró diferencia significativa para OS y SLP en ambas ramas. El análisis multivariante reflejó que SUVmax pre-tratamiento no constituía un factor predictivo de OS (HR 1,099, p=0,726) y SLP (HR 1,022, p=0,941).

Conclusiones

El índice SUVmax con un valor límite de 15 con respecto al tumor primario pre-tratamiento no tiene valor pronóstico en nuestro grupo de pacientes de CPCP en estadio III, tratados con CCRT definitiva.

Palabras clave:
Pronostico
18F-FDG PET/CT
Quimioradioterapia
Cancer de pulmon

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.